WilmerHale advised Syros Pharmaceuticals, Inc., a life sciences company, in its initial public offering. The company intends to use the proceeds to fund its proof-of-concept Phase II clinical trial of SY-1425 in acute myelogenous leukemia and myelodysplastic syndrome, including clinical research outsourcing, drug manufacturing, companion diagnostic development and internal personnel costs. The offering is expected to close on July 6, 2016, subject to customary closing conditions.
The WilmerHale team on the transaction was led by Partner Steven Singer and included Special Counsel Cynthia Mazareas, Senior Associate Stephanie Singer and Associate Killian Nolan.
Read Syros Pharmaceuticals' press release for more information.